PharmaCyte Biotech, Inc. (PMCB) - Dilution Analysis

10-Q filing | 10.7M shares outstanding

10-Q filing | 10.1M shares outstanding

10-Q filing | 6.8M shares outstanding

8-K filing: PharmaCyte Biotech, Inc. purchased Series H convertible preferred stock and warrants from TNF Pharmaceuticals, Inc. for $3,000,000, which closed on September 4, 2025. ($6.0M proceeds)

8-K filing: PharmaCyte Biotech, Inc. entered into a Securities Purchase Agreement to sell Series C convertible preferred stock and warrants in a private placement, expecting gross proceeds of $7 million. ($7.0M proceeds)

10-Q filing | 7.0M shares outstanding

10-Q filing | 7.6M shares outstanding

10-Q filing | 7.9M shares outstanding

10-K filing | 7.7M shares outstanding

8-K filing: PharmaCyte Biotech, Inc. entered into a Securities Purchase Agreement with MyMD Pharmaceuticals, Inc. to purchase preferred stock convertible into 3,854,626 shares of MyMD's common stock, warrants to purchase up to 3,854,626 MyMD Common Shares with a five-year term and warrants to purchase up to 3,854,626 MyMD Common Shares with an 18-month term for $7,000,000.

10-Q filing | 8.6M shares outstanding

10-Q filing | 8.8M shares outstanding

8-K filing: PharmaCyte Biotech, Inc. entered into a Securities Purchase Agreement with Femasys Inc. to purchase senior unsecured convertible notes and warrants convertible into Femasys common stock for an aggregate principal amount of $5,000,000.

S-3/A filing: This prospectus relates to the resale or other disposition from time to time of up to an aggregate of 153,866,938 shares of our common stock issuable upon the conversion of shares of our newly designated Series B convertible preferred stock and shares of our Common Stock issuable upon exercise of warrants.

10-Q filing | 8.8M shares outstanding

S-3/A filing: This prospectus relates to the resale or other disposition from time to time of up to an aggregate of 153,866,938 shares of our common stock issuable upon the conversion of shares of our newly designated Series B convertible preferred stock and shares of our Common Stock issuable upon exercise of warrants.

S-3/A filing: This S-3/A filing relates to the resale of up to 3,357,116 shares of common stock issuable upon the conversion of Series B convertible preferred stock and exercise of warrants.

10-K filing | 8.8M shares outstanding

S-3 filing: Registration of 100,000,000 shares of common stock issuable upon conversion of Series B convertible preferred stock and exercise of warrants for resale by selling stockholders.

8-K filing: PharmaCyte Biotech, Inc. completed a private placement of Series B convertible preferred stock and warrants, raising $35 million, and announced a tender offer to repurchase up to 7,750,000 shares of its common stock. ($35.0M proceeds)

10-Q filing | 19.0M shares outstanding

8-K filing: PharmaCyte Biotech, Inc. authorized a share repurchase program to repurchase up to $10 million of its outstanding common stock, effective immediately for a two-year period. ($9.3M proceeds)

10-Q filing | 20.6M shares outstanding

10-Q filing | 20.8M shares outstanding

10-K filing | 20.7M shares outstanding

10-Q filing | 21.7M shares outstanding

10-Q filing | 20.7M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling stockholders of up to 8,050,000 shares of PharmaCyte Biotech, Inc.'s common stock, issued pursuant to the exercise of warrants.

10-Q filing | 20.7M shares outstanding

8-K filing: PharmaCyte Biotech, Inc. entered into a securities purchase agreement to sell 8,430,000 shares of common stock and pre-funded warrants to purchase up to 5,570,000 shares of common stock in a registered direct offering, and also agreed to issue unregistered warrants to purchase up to 7,000,000 shares of common stock in a concurrent private placement, expecting to receive gross proceeds of approximately $70 million. ($69.99M proceeds)

8-K filing: PharmaCyte Biotech, Inc. entered into an underwriting agreement with H.C. Wainwright & Co., LLC for a public offering of common stock, pre-funded warrants, and common stock warrants at a combined price of $4.25 per share, expecting gross proceeds of approximately $15 million. ($15.0M proceeds)

10-K filing | 1.1M shares outstanding

8-K filing: Stock split 1-for-1,500 | Outstanding: 2,341,410,405 → 1,560,940

S-3 filing: Pharmacyte Biotech, Inc. files an S-3 form to offer and sell up to $100,000,000.00 of its common stock, preferred stock, debt securities, warrants and rights, or any combination of these securities.

10-Q filing | 1638.6M shares outstanding

10-Q filing | 1638.6M shares outstanding

10-Q filing | 1638.6M shares outstanding

10-K filing | 1100.1M shares outstanding

10-Q filing | 1481.5M shares outstanding

8-K filing: PharmaCyte Biotech, Inc. closed a private placement on January 21, 2020, issuing 30,000,000 restricted shares of common stock at $0.005 per share, for gross proceeds of $150,000. ($0.15M proceeds)